From tumor immunosuppression to eradication: Targeting homing and activity of immune effector cells to tumors

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Draghiciu, Oana ^a   Nijman, Hans W ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ATRASENTAN; CARBOPLATIN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; WART VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ERADICATION THERAPY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MELANOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; HOMEOSTASIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NEOPLASM;

HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS;

EID: 84855573778     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/439053     Document Type: Review

References (175)

1. Burnet F. M., The concept of immunological surveillance Progress in Experimental Tumor Research 1970 13 1 27
2. Malmberg K. J., Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunology, Immunotherapy 2004 53 10 879 892
3. Mapara M. Y., Sykes M., Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance Journal of Clinical Oncology 2004 22 6 1136 1151 (Pubitemid 41095048)
4. Smyth M. J., Godfrey D. I., Trapani J. A., A fresh look at tumor immunosurveillance and immunotherapy Nature Immunology 2001 2 4 293 299 (Pubitemid 33706339)
5. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape Nature Immunology 2002 3 11 991 998 (Pubitemid 35363648)
6. Dunn G. P., Koebel C. M., Schreiber R. D., Interferons, immunity and cancer immunoediting Nature Reviews Immunology 2006 6 11 836 848 (Pubitemid 44631652)
7. Sogn J. A., Tumor immunology: the glass is half full Immunity 1998 9 6 757 763 (Pubitemid 29024455)
8. Gabrilovich D. I., Ciernik I. F., Carbone D. P., Dendritic cells in antitumor immune responses I. Defective antigen presentation in tumor-bearing hosts Cellular Immunology 1996 170 1 101 110
9. Troy A. J., Summers K. L., Davidson P. J., Atkinson C. H., Hart D. N., Minimal recruitment and activation of dendritic cells within renal cell carcinoma Clinical Cancer Research 1998 4 3 585 593 (Pubitemid 28193556)
10. Gabrilovich D. I., Corak J., Ciernik I. F., Kavanaugh D., Carbone D. P., Decreased antigen presentation by dendritic cells in patients with breast cancer Clinical Cancer Research 1997 3 3 483 490 (Pubitemid 27158075)
11. Coventry B. J., Lee P. L., Gibbs D., Hart D. N., Dendritic cell density and activation status in human breast cancerCD 1 a, CMRF-44, CMRF-56 and CD-83 expression British Journal of Cancer 2002 86 4 546 551 (Pubitemid 34185090)
12. Fiore F., von Bergwelt-Baildon M. S., Drebber U., Beyer M., Popov A., Manzke O., Wickenhauser C., Baldus S. E., Schultze J. L., Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L Leukemia and Lymphoma 2006 47 4 613 622
13. von Bergwelt-Baildon M. S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M. S., Fiore F., Roth U., Beyer M., Debey S., Wickenhauser C., Hanisch F. G., Schultze J. L., CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition Blood 2006 108 1 228 237 (Pubitemid 43990633)
14. Schoenborn J. R., Wilson C. B., Regulation of interferon- during innate and adaptive immune responses Advances in Immunology 2007 96 41 101 (Pubitemid 350018717)
15. Demeure C. E., Yang L. P., Byun D. G., Ishihara H., Vezzio N., Delespesse G., Human naive CD4 T cells produce interleukin-4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions European Journal of Immunology 1995 25 9 2722 2725
16. Tomiyama H., Takata H., Matsuda T., Takiguchi M., Phenotypic classification of human CD8 + T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function European Journal of Immunology 2004 34 4 999 1010 (Pubitemid 39255978)
17. Curtsinger J. M., Lins D. C., Mescher M. F., CD8 + memory T cells (CD44 high, Ly-6C +) are more sensitive than naive cells (CD44 low, Ly-6C -) to TCR/CD8 signaling in response to antigen Journal of Immunology 1998 160 7 3236 3243 (Pubitemid 28164712)
18. Kilinc M. O., Gu T., Harden J. L., Virtuoso L. P., Egilmez N. K., Central role of tumor-associated CD8 + T effector/memory cells in restoring systemic antitumor immunity Journal of Immunology 2009 182 7 4217 4225
19. Wherry E. J., Teichgrber V., Becker T. C., Masopust D., Kaech S. M., Antia R., von Andrian U. H., Ahmed R., Lineage relationship and protective immunity of memory CD8 T cell subsets Nature Immunology 2003 4 3 225 234 (Pubitemid 36322131)
20. Klebanoff C. A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A. R., Finkelstein S. E., Palmer D. C., Antony P. A., Hwang S. T., Rosenberg S. A., Waldmann T. A., Restifo N. P., Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells Proceedings of the National Academy of Sciences of the United States of America 2005 102 27 9571 9576 (Pubitemid 40981722)
21. Kilinc M. O., Aulakh K. S., Nair R. E., Jones S. A., Alard P., Kosiewicz M. M., Egilmez N. K., Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8 + T effectors Journal of Immunology 2006 177 10 6962 6973 (Pubitemid 44715062)
22. Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gurney A. L., Hillan K. J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A., Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 1998 396 6712 699 703 (Pubitemid 29003951)
23. Gastman B. R., Atarashi Y., Reichert T. E., Saito T., Balkir L., Rabinowich H., Whiteside T. L., Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes Cancer Research 1999 59 20 5356 5364 (Pubitemid 29504005)
24. zren N., El-Deiry W. S., Cell surface death receptor signaling in normal and cancer cells Seminars in Cancer Biology 2003 13 2 135 147 (Pubitemid 36321814)
25. Li M. O., Flavell R. A., TGF- : a master of all T cell trades Cell 2008 134 3 392 404
26. Thomas D. A., Massagué J., TGF- directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 2005 8 5 369 380 (Pubitemid 41579832)
27. Yu Z., Restifo N. P., Cancer vaccines: progress reveals new complexities The Journal of Clinical Investigation 2002 110 3 289 294 (Pubitemid 34847958)
28. Antony P. A., Restifo N. P., Do CD4 + CD25 + immunoregulatory T cells hinder tumor immunotherapy? Journal of Immunotherapy 2002 25 3 202 206 (Pubitemid 34533309)
29. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance Nature Reviews Cancer 2005 5 4 263 274 (Pubitemid 40488632)
30. Gelderman K. A., Tomlinson S., Ross G. D., Gorter A., Complement function in mAb-mediated cancer immunotherapy Trends in Immunology 2004 25 3 158 164 (Pubitemid 38249490)
31. Lamagna C., Aurrand-Lions M., Imhof B. A., Dual role of macrophages in tumor growth and angiogenesis Journal of Leukocyte Biology 2006 80 4 705 713 (Pubitemid 44835885)
32. Ohri C. M., Shikotra A., Green R. H., Waller D. A., Bradding P., Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival European Respiratory Journal 2009 33 1 118 126
33. Bonnotte B., Larmonier N., Favre N., Fromentin A., Moutet M., Martin M., Gurbuxani S., Solary E., Chauffert B., Martin F., Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system Journal of Immunology 2001 167 9 5077 5083 (Pubitemid 33009741)
34. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 2 137 148 (Pubitemid 39094044)
35. Gordon S., Alternative activation of macrophages Nature Reviews Immunology 2003 3 1 23 35 (Pubitemid 37328697)
36. Lucas T., Abraham D., Aharinejad S., Modulation of tumor associated macrophages in solid tumors Frontiers in Bioscience 2008 13 5580 5588
37. Murdoch C., Giannoudis A., Lewis C. E., Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood 2004 104 8 2224 2234 (Pubitemid 39331817)
38. Bergers G., Coussens L. M., Extrinsic regulators of epithelial tumor progression: metalloproteinases Current Opinion in Genetics and Development 2000 10 1 120 127 (Pubitemid 30113715)
39. Lepique A. P., Daghastanli K. R., Cuccovia I. M., Villa L. L., HPV16 tumor associated macrophages suppress antitumor T cell responses Clinical Cancer Research 2009 15 13 4391 4400
40. Bolpetti A., Silva J. S., Villa L. L., Lepique A. P., Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth BMC Immunology 2010 11, article 27
41. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V., Myeloid-derived suppressor cell heterogeneity and subset definition Current Opinion in Immunology 2010 22 2 238 244
42. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system Nature Reviews Immunology 2009 9 3 162 174
43. Zhu B., Bando Y., Xiao S., Yang K., Anderson A. C., Kuchroo V. K., Khoury S. J., CD11b+Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis Journal of Immunology 2007 179 8 5228 5237
44. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer Journal of Immunology 2009 182 8 4499 4506
45. Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D. I., antigen-specific inhibition of CD8 + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species Journal of Immunology 2004 172 2 989 999 (Pubitemid 38113758)
46. Ochoa A. C., Zea A. H., Hernandez C., Rodriguez P. C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma Clinical Cancer Research 2007 13 2 721s 726s
47. Almand B., Clark J. I., Nikitina E., Van Beynen J., English N. R., Knight S. C., Carbone D. P., Gabrilovich D. I., Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer Journal of Immunology 2001 166 1 678 689 (Pubitemid 32038493)
48. Gabrilovich D. I., Bronte V., Chen S. -H., Colombo M. P., Ochoa A., Ostrand-Rosenberg S., Schreiber H., The terminology issue for myeloid-derived suppressor cells Cancer Research 2007 67 1 425 (Pubitemid 46142802)
49. Sinha P., Clements V. K., Miller S., Ostrand-Rosenberg S., Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression Cancer Immunology, Immunotherapy 2005 54 11 1137 1142 (Pubitemid 41396817)
50. Sinha P., Clements V. K., Ostrand-Rosenberg S., Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis Cancer Research 2005 65 24 11743 11751 (Pubitemid 41821736)
51. Serafini P., Borrello I., Bronte V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Seminars in Cancer Biology 2006 16 1 53 65 (Pubitemid 43139709)
52. Yanagisawa K., Exley M. A., Jiang X., Ohkochi N., Taniguchi M., Seino K. I., Hyporesponsiveness to natural killer T-cell ligand -galactosylceramide in cancer-bearing state mediated by CD11b + Gr-1 + cells producing nitric oxide Cancer Research 2006 66 23 11441 11446 (Pubitemid 46009976)
53. Yang R., Cai Z., Zhang Y., Yutzy W. H. IIII, Roby K. F., Roden R. B. S., CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1 + CD11b + myeloid cells Cancer Research 2006 66 13 6807 6815 (Pubitemid 44085641)
54. Bronte V., Zanovello P., Regulation of immune responses by L-arginine metabolism Nature Reviews Immunology 2005 5 8 641 654 (Pubitemid 41113195)
55. Rodrguez P. C., Ochoa A. C., Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives Immunological Reviews 2008 222 1 180 191 (Pubitemid 351430370)
56. Goo O., Alcaide P., Fresno M., Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1+)CD11b+ immature myeloid suppressor cells International Immunology 2002 14 10 1125 1134 (Pubitemid 35175220)
57. Harari O., Liao J. K., Inhibition of MHC II gene transcription by nitric oxide and antioxidants Current Pharmaceutical Design 2004 10 8 893 898 (Pubitemid 38380067)
58. Bingisser R. M., Tilbrook P. A., Holt P. G., Kees U. R., Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway Journal of Immunology 1998 160 12 5729 5734 (Pubitemid 28298028)
59. Nagaraj S., Gabrilovich D. I., Myeloid-derived suppressor cells in human cancer Cancer Journal 2010 16 4 348 353
60. Srivastava M. K., Sinha P., Clements V. K., Rodriguez P., Ostrand-Rosenberg S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Research 2010 70 1 68 77
61. Bentz B. G., Haines G. K. III, Radosevich J. A., Increased protein nitrosylation in head and neck squamous cell carcinogenesis Head and Neck 2000 22 1 64 70 (Pubitemid 30030671)
62. Sinha P., Clements V. K., Fulton A. M., Ostrand-Rosenberg S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Research 2007 67 9 4507 4513 (Pubitemid 46815102)
63. Tomihara K., Guo M., Shin T., Sun X., Ludwig S. M., Brumlik M. J., Zhang B., Curiel T. J., Shin T., Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b + Gr-1 + cells Journal of Immunology 2010 184 11 6151 6160
64. Kabelitz D., Wesch D., Oberg H. H., Regulation of regulatory T cells: role of dendritic cells and toll-like receptors Critical Reviews in Immunology 2006 26 4 291 305 (Pubitemid 44423548)
65. Visser J., Nijman H. W., Hoogenboom B. N., Jager P., Van Baarle D., Schuuring E., Abdulahad W., Miedema F., Van Der Zee A. G., Daemen T., Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia Clinical and Experimental Immunology 2007 150 2 199 209 (Pubitemid 47609556)
66. Fontenot J. D., Gavin M. A., Rudensky A. Y., Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells Nature Immunology 2003 4 4 330 336 (Pubitemid 36432314)
67. Shevach E. M., Fatal attraction: tumors beckon regulatory T cells Nature Medicine 2004 10 9 900 901 (Pubitemid 39273725)
68. Shevach E. M., Regulatory T cells. Introduction Seminars in Immunology 2004 16 2 69 71
69. O'Garra A., Vieira P., Regulatory T cells and mechanisms of immune system control Nature Medicine 2004 10 8 801 805 (Pubitemid 39070850)
70. O'Garra A., Vieira P. L., Vieira P., Goldfeld A. E., IL-10-producing and naturally occurring CD4 + Tregs: limiting collateral damage The Journal of Clinical Investigation 2004 114 10 1372 1378 (Pubitemid 40385564)
71. Yi H., Zhen Y., Jiang L., Zheng J., Zhao Y., The phenotypic characterization of naturally occurring regulatory CD4 + CD25 + T cells Cellular amp; molecular immunology 2006 3 3 189 195
72. Ito T., Hanabuchi S., Wang Y. H., Park W. R., Arima K., Bover L., Qin F. X. F., Gilliet M., Liu Y. J., Two functional subsets of FOXP3 + regulatory T cells in human thymus and periphery Immunity 2008 28 6 870 880
73. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S., Stimulation of CD25 + CD4 + regulatory T cells through GITR breaks immunological self-tolerance Nature Immunology 2002 3 2 135 142 (Pubitemid 34141443)
74. Feuerer M., Hill J. A., Mathis D., Benoist C., Foxp3 + regulatory T cells: differentiation, specification, subphenotypes Nature Immunology 2009 10 7 689 695
75. Zou W., Regulatory T cells, tumour immunity and immunotherapy Nature Reviews Immunology 2006 6 4 295 307
76. Fontenot J. D., Rasmussen J. P., Williams L. M., Dooley J. L., Farr A. G., Rudensky A. Y., Regulatory T cell lineage specification by the forkhead transcription factor Foxp3 Immunity 2005 22 3 329 341 (Pubitemid 40387475)
77. Sasada T., Kimura M., Yoshida Y., Kanai M., Takabayashi A., CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression Cancer 2003 98 5 1089 1099 (Pubitemid 37022112)
78. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949 (Pubitemid 39273735)
79. Sakaguchi S., Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self Nature Immunology 2005 6 4 345 352 (Pubitemid 41716771)
80. Malek T. R., Bayer A. L., Tolerance, not immunity, crucially depends on IL-2 Nature Reviews Immunology 2004 4 9 665 674 (Pubitemid 39223073)
81. Zheng S. G., Wang J. H., Gray J. D., Soucier H., Horwitz D. A., Natural and induced CD4 + CD25 + cells educate CD4 + CD25 - cells to develop suppressive activity: the role of IL-2, TGF-, and IL-10 Journal of Immunology 2004 172 9 5213 5221 (Pubitemid 38542018)
82. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M. C., von Boehmer H., Inducing and expanding regulatory T cell populations by foreign antigen Nature Immunology 2005 6 12 1219 1227 (Pubitemid 43045633)
83. Steinman L., A brief history of T H 17, the first major revision in the T H 1/T H 2 hypothesis of T cell-mediated tissue damage Nature Medicine 2007 13 2 139 145
84. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., Valmori D., Human memory FOXP3 + Tregs secrete IL-17 ex vivo and constitutively express the T H 17 lineage-specific transcription factor ROR t Proceedings of the National Academy of Sciences of the United States of America 2009 106 21 8635 8640
85. Harrington L. E., Hatton R. D., Mangan P. R., Turner H., Murphy T. L., Murphy K. M., Weaver C. T., Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nature Immunology 2005 6 11 1123 1132 (Pubitemid 41541790)
86. Benchetrit F., Ciree A., Vives V., Warnier G., Gey A., Sauts-Fridman C., Fossiez F., Haicheur N., Fridman W. H., Tartour E., Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism Blood 2002 99 6 2114 2121 (Pubitemid 34525496)
87. Charles K. A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., Chakravarty P., Thompson R. G., Kollias G., Smyth J. F., Balkwill F. R., Hagemann T., The tumor-promoting actions of TNF- involve TNFR1 and IL-17 in ovarian cancer in mice and humans The Journal of Clinical Investigation 2009 119 10 3011 3023
88. Bagnato A., Rosan L., The endothelin axis in cancer International Journal of Biochemistry and Cell Biology 2008 40 8 1443 1451
89. Nakamura S., Naruse M., Naruse K., Demura H., Uemura H., Immunocytochemical localization of endothelin in cultured bovine endothelial cells Histochemistry 1990 94 5 475 477 (Pubitemid 20303240)
90. Levin E. R., Endothelins New England Journal of Medicine 1995 333 6 356 363
91. Buckanovich R. J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., Katsaros D., O'Brien-Jenkins A., Gimotty P. A., Coukos G., Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy Nature Medicine 2008 14 1 28 36
92. Gohji K., Kitazawa S., Tamada H., Katsuoka Y., Nakajima M., Expression of endothelin receptor A associated with prostate cancer progression Journal of Urology 2001 165 3 1033 1036 (Pubitemid 32156344)
93. Venuti A., Salani D., Manni V., Poggiali F., Bagnato A., Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy The FASEB Journal 2000 14 14 2277 2283
94. Bagnato A., Cirilli A., Salani D., Simeone P., Muller A., Nicotra M. R., Natali P. G., Venuti A., Growth inhibition of cervix carcinoma cells in vivo by endothelin a receptor blockade Cancer Research 2002 62 22 6381 6384 (Pubitemid 35364090)
95. Eltze E., Bertolin M., Korsching E., Wlfing P., Maggino T., Lellé R., Expression and prognostic relevance of endothelin-B receptor in vulvar cancer Oncology Reports 2007 18 2 305 311
96. Ishida Y., Agata Y., Shibahara K., Honjo T., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death The EMBO Journal 1992 11 11 3887 3895
97. Nishimura H., Nose M., Hiai H., Minato N., Honjo T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 1999 11 2 141 151 (Pubitemid 29428807)
98. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., Honjo T., Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 2001 291 5502 319 322 (Pubitemid 32096320)
99. Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H., PD-1 and its ligands in tolerance and immunity Annual Review of Immunology 2008 26 677 704 (Pubitemid 351600389)
100. Barber D. L., Wherry E. J., Masopust D., Zhu B., Allison J. P., Sharpe A. H., Freeman G. J., Ahmed R., Restoring function in exhausted CD8 T cells during chronic viral infection Nature 2006 439 7077 682 687 (Pubitemid 43237609)
101. Freeman G. J., Long A. J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L. J., Malenkovich N., Okazaki T., Byrne M. C., Horton H. F., Fouser L., Carter L., Ling V., Bowman M. R., Carreno B. M., Collins M., Wood C. R., Honjo T., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation Journal of Experimental Medicine 2000 192 7 1027 1034
102. Curiel T. J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K. L., Daniel B., Zimmermann M. C., David O., Burow M., Gordon A., Dhurandhar N., Myers L., Berggren R., Hemminki A., Alvarez R. D., Emilie D., Curiel D. T., Chen L., Zou W., Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nature Medicine 2003 9 5 562 567 (Pubitemid 36597102)
103. Parry R. V., Chemnitz J. M., Frauwirth K. A., Lanfranco A. R., Braunstein I., Kobayashi S. V., Linsley P. S., Thompson C. B., Riley J. L., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Molecular and Cellular Biology 2005 25 21 9543 9553 (Pubitemid 41507854)
104. Huang C. T., Workman C. J., Flies D., Pan X., Marson A. L., Zhou G., Hipkiss E. L., Ravi S., Kowalski J., Levitsky H. I., Powell J. D., Pardoll D. M., Drake C. G., Vignali D. A. A., Role of LAG-3 in regulatory T cells Immunity 2004 21 4 503 513 (Pubitemid 39370506)
105. Medema J. P., de Jong J., Peltenburg L. T., Verdegaal E. M. E., Gorter A., Bres S. A., Franken K. L. M. C., Hahne M., Albar J. P., Melief C. J. M., Offringa R., Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11515 11520 (Pubitemid 32928760)
106. Cresswell A. C., Sisley K., Laws D., Parsons M. A., Rennie I. G., Murray A. K., Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease Melanoma Research 2001 11 3 275 281 (Pubitemid 32578814)
107. Munn D. H., Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation Current Opinion in Immunology 2006 18 2 220 225 (Pubitemid 43327306)
108. Ganswindt U., Paulsen F., Corvin S., Eichhorn K., Glocker S., Hundt I., Birkner M., Alber M., Anastasiadis A., Stenzl A., Bares R., Budach W., Bamberg M., Belka C., Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition BMC Cancer 2005 5, article 91
109. Gajewski T. F., Meng Y., Harlin H., Immune suppression in the tumor microenvironment Journal of Immunotherapy 2006 29 3 233 240 (Pubitemid 44297291)
110. Gajewski T. F., Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment Clinical Cancer Research 2006 12 7, part 2 2326s 2330s
111. Ganss R., Ryschich E., Klar E., Arnold B., Hmmerling G. J., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication Cancer Research 2002 62 5 1462 1470 (Pubitemid 34407808)
112. Lugade A. A., Moran J. P., Gerber S. A., Rose R. C., Frelinger J. G., Lord E. M., Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor Journal of Immunology 2005 174 12 7516 7523 (Pubitemid 40806254)
113. Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T. O., Babb J. S., Schneider R. J., Formenti S. C., Dustin M. L., Demaria S., Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells Journal of Immunology 2008 181 5 3099 3107
114. Quezada S. A., Peggs K. S., Simpson T. R., Shen Y., Littman D. R., Allison J. P., Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma Journal of Experimental Medicine 2008 205 9 2125 2138
115. Khan M. A., Partin A. W., Endothelin-a receptor antagonists and advanced prostate cancer Reviews in Urology 2004 6 1 47 48
116. Akhavan A., McHugh K. H., Guruli G., Bies R. R., Zamboni W. C., Strychor S., Nelson J. B., Pflug B. R., Endothelin receptor A blockade enhances taxane effects in prostate cancer Neoplasia 2006 8 9 725 732 (Pubitemid 44465524)
117. Kandalaft L. E., Facciabene A., Buckanovich R. J., Coukos G., Endothelin B receptor, a new target in cancer immune therapy Clinical Cancer Research 2009 15 14 4521 4528
118. Bagnato A., Rosan L., Spinella F., Di Castro V., Tecce R., Natali P. G., Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression Cancer Research 2004 64 4 1436 1443 (Pubitemid 38235614)
119. Lffler A., Kufer P., Lutterbse R., Zettl F., Daniel P. T., Schwenkenbecher J. M., Riethmller G., Drken B., Bargou R. C., A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 2000 95 6 2098 2103 (Pubitemid 30151651)
120. Marmé A., Strauass G., Bastert G., Grischke E. M., Moldenhauer G., Intraperitoneal bispecific antibody (HEA125XOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma International Journal of Cancer 2002 101 2 183 189 (Pubitemid 34970911)
121. Daniel P. T., Kroidl A., Kopp J., Sturm I., Moldenhauer G., Drken B., Pezzutto A., Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents 'veto' apoptosis of antibody-targeted cytotoxic T cells Blood 1998 92 12 4750 4757 (Pubitemid 29005877)
122. Haldar S., Jena N., Croce C. M., Inactivation of Bcl-2 by phosphorylation Proceedings of the National Academy of Sciences of the United States of America 1995 92 10 4507 4511
123. Dirkx A. E., Oude Egbrink M. G., Castermans K., van der Schaft D. W., Thijssen V. L., Dings R. P., Kwee L., Mayo K. H., Wagstaff J., Bouma-ter Steege J. C., Griffioen A. W., Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors The FASEB Journal 2006 20 6 621 630 (Pubitemid 44933306)
124. Nagaraj S., Youn J. I., Weber H., Iclozan C., Lu L., Cotter M. J., Meyer C., Becerra C. R., Fishman M., Antonia S., Sporn M. B., Liby K. T., Rawal B., Lee J. -H., Gabrilovich D. I., Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer Clinical Cancer Research 2010 16 6 1812 1823
125. Sasahira T., Sasaki T., Kuniyasu H., Interleukin-15 and transforming growth factor are associated with depletion of tumor-associated macrophages in colon cancer Journal of Experimental and Clinical Cancer Research 2005 24 1 69 74 (Pubitemid 40655865)
126. Gazzaniga S., Bravo A. I., Guglielmotti A., Van Rooijen N., Maschi F., Vecchi A., Mantovani A., Mordoh J., Wainstok R., Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft The Journal of Investigative Dermatology 2007 127 8 2031 2041 (Pubitemid 47075380)
127. Lewen S., Zhou H., Hu H. D., Cheng T., Markowitz D., Reisfeld R. A., Xiang R., Luo Y., A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis Cancer Immunology, Immunotherapy 2008 57 4 507 515 (Pubitemid 351170534)
128. Zeisberger S., Odermatt B., Marty C., Zehnder-Fjllman A. H. M., Ballmer-Hofer K., Schwendener R. A., Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach British Journal of Cancer 2006 95 3 272 281 (Pubitemid 44187587)
129. Giraudo E., Inoue M., Hanahan D., An amino-bisphosphonate targets MMP-9-Expressing macrophages and angiogenesis to impair cervical carcinogenesis The Journal of Clinical Investigation 2004 114 5 623 633 (Pubitemid 39578752)
130. Ko J. S., Zea A. H., Rini B. I., Ireland J. L., Elson P., Cohen P., Golshayan A., Rayman P. A., Wood L., Garcia J., Dreicer R., Bukowski R., Finke J. H., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clinical Cancer Research 2009 15 6 2148 2157
131. Ko J. S., Rayman P., Ireland J., Swaidani S., Li G., Bunting K. D., Rini B., Finke J. H., Cohen P. A., Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Research 2010 70 9 3526 3536
132. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., Martin F., Apetoh L., Rébé C., Ghiringhelli F., 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Research 2010 70 8 3052 3061
133. Le H. K., Graham L., Cha E., Morales J. K., Manjili M. H., Bear H. D., Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice International Immunopharmacology 2009 9 7-8 900 909
134. Shimizu J., Yamazaki S., Sakaguchi S., Induction of tumor immunity by removing CD25 + CD4 + T cells: a common basis between tumor immunity and autoimmunity Journal of Immunology 1999 163 10 5211 5218
135. Klages K., Mayer C. T., Lahl K., Loddenkemper C., Teng M. W. L., Ngiow S. F., Smyth M. J., Hamann A., Huehn J., Sparwasser T., Selective depletion of Foxp3 + regulatory T cells improves effective therapeutic vaccination against established melanoma Cancer Research 2010 70 20 7788 7799
136. Walczak M., Regts J., van Oosterhout A. J., Boon L., Wilschut J., Nijman H. W., Daemen T., Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system Antiviral Therapy 2011 16 2 207 218
137. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T. W., Sakaguchi S., Immunologic self-tolerance maintained by CD25 + CD4 + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4 Journal of Experimental Medicine 2000 192 2 303 310
138. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S., Stimulation of CD25 + CD4 + regulatory T cells through GITR breaks immunological self-tolerance Nature Immunology 2002 3 2 135 142 (Pubitemid 34141443)
139. Peng G., Guo Z., Kiniwa Y., Voo K. S., Peng W., Fu T., Wang D. Y., Li Y., Wang H. Y., Wang R. F., Immunology: toll-like receptor 8-mediated reversal of CD4 + regulatory T cell function Science 2005 309 5739 1380 1384 (Pubitemid 41209366)
140. Zea A. H., Rodriguez P. C., Atkins M. B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A. C., Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion Cancer Research 2005 65 8 3044 3048 (Pubitemid 40524582)
141. Talmadge J. E., Hood K. C., Zobel L. C., Shafer L. R., Coles M., Toth B.,
142. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., Battistini L., Iafrate M., Prayer-Galetti T., Pagano F., Viola A., Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers Journal of Experimental Medicine 2005 201 8 1257 1268 (Pubitemid 40629069)
143. Gabrilovich D. I., Velders M. P., Sotomayor E. M., Kast W. M., Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells Journal of Immunology 2001 166 9 5398 5406 (Pubitemid 32374159)
144. Song H., Wang R., Wang S., Lin J., A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells Proceedings of the National Academy of Sciences of the United States of America 2005 102 13 4700 4705 (Pubitemid 40471517)
145. Iwai Y., Terawaki S., Honjo T., PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells International Immunology 2005 17 2 133 144 (Pubitemid 40246578)
146. Pilon-Thomas S., Mackay A., Vohra N., Mulé J. J., Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma Journal of Immunology 2010 184 7 3442 3449
147. Grosso J. F., Kelleher C. C., Harris T. J., Maris C. H., Hipkiss E. L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T. C., Goldberg M. V., Pardoll D. M., Drake C. G., LAG-3 regulates CD8 + T cell accumulation and effector function in murine self- and tumor-tolerance systems The Journal of Clinical Investigation 2007 117 11 3383 3392 (Pubitemid 350096994)
148. Grosso J. F., Goldberg M. V., Getnet D., Bruno T. C., Yen H. -R., Pyle K. J., Hipkiss E., Vignali D. A.A., Pardoll D. M., Drake C. G., Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells Journal of Immunology 2009 182 11 6659 6669
149. Zhang Q., Yang X., Pins M., Javonovic B., Kuzel T., Kim S. J., Van Parijs L., Greenberg N. M., Liu V., Guo Y., Lee C., Adoptive transfer of tumor-reactive transforming growth factor- -insensitive CD8 + T cells: eradication of autologous mouse prostate cancer Cancer Research 2005 65 5 1761 1769 (Pubitemid 40478602)
150. Wang F. L., Qin W. J., Wen W. H., Tian F., Song B., Zhang Q., Lee C., Zhong W. D., Guo Y. L., Wang H., TGF- insensitive dendritic cells: an efficient vaccine for murine prostate cancer Cancer Immunology, Immunotherapy 2007 56 11 1785 1793 (Pubitemid 47313083)
151. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B. J., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nature Medicine 2003 9 10 1269 1274 (Pubitemid 37279849)
152. Munn D. H., Sharma M. D., Hou D., Baban B., Lee J. R., Antonia S. J., Messina J. L., Chandler P., Koni P. A., Mellor A. L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes The Journal of Clinical Investigation 2004 114 2 280 290 (Pubitemid 39071633)
153. Yee C., Adoptive T cell therapy: addressing challenges in cancer immunotherapy Journal of Translational Medicine 2005 3, article 17
154. June C. H., Principles of adoptive T cell cancer therapy The Journal of Clinical Investigation 2007 117 5 1204 1212 (Pubitemid 46718405)
155. June C. H., Adoptive T cell therapy for cancer in the clinic The Journal of Clinical Investigation 2007 117 6 1466 1476 (Pubitemid 46871329)
156. Rosenberg S. A., Restifo N. P., Yang J. C., Morgan R. A., Dudley M. E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nature Reviews Cancer 2008 8 4 299 308 (Pubitemid 351430867)
157. Khattar M., Chen W., Stepkowski S. M., Expanding and converting regulatory T cells: a horizon for immunotherapy Archivum Immunologiae et Therapiae Experimentalis 2009 57 3 199 204
158. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C. C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 2009 114 3 535 546
159. Gattinoni L., Finkelstein S. E., Klebanoff C. A., Antony P. A., Palmer D. C., Spiess P. J., Hwang L. N., Yu Z., Wrzesinski C., Heimann D. M., Surh C. D., Rosenberg S. A., Restifo N. P., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells Journal of Experimental Medicine 2005 202 7 907 912 (Pubitemid 41396891)
160. Johnson L. A., Heemskerk B., Powell Jr. D. J., Cohen C. J., Morgan R. A., Dudley M. E., Robbins P. F., Rosenberg S. A., Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes Journal of Immunology 2006 177 9 6548 6559 (Pubitemid 44628874)
161. Dudley M. E., Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens Journal of Clinical Oncology 2008 26 32 5233 5239
162. Tseng C. W., Trimble C., Zeng Q., Monie A., Alvarez R. D., Huh W. K., Hoory T., Wang M. C., Hung C. F., Wu T. C., Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts Cancer Immunology, Immunotherapy 2009 58 5 737 748
163. Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., Tsuda H., Sugiyama T., Kodama S., Kimura E., Ochiai K., Noda K., Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial The Lancet 2009 374 9698 1331 1338
164. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Ménard C., Ghiringhelli F., Terme M., Carpentier A. F., Darrasse-Jse G., Lemonnier F., Zitvogel L., Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines Journal of Immunology 2006 176 5 2722 2729
165. Viaud S., Flament C., Zoubir M., Pautier P., LeCesne A., Ribrag V., Soria J. -C., Marty V., Vielh P., Robert C., Chaput N., Zitvogel L., Cyclophosphamide induces differentiation of Th17 cells in cancer patients Cancer Research 2011 71 3 661 665
166. Parkin D. M., The global health burden of infection-associated cancers in the year 2002 International Journal of Cancer 2006 118 12 3030 3044
167. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer New England Journal of Medicine 2010 363 5 411 422
168. Small E. J., Schellhammer P. F., Higano C. S., Redfern C. H., Nemunaitis J. J., Valone F. H., Verjee S. S., Jones L. A., Hershberg R. M., Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer Journal of Clinical Oncology 2006 24 19 3089 3094 (Pubitemid 46638945)
169. Daemen T., Regts J., Holtrop M., Wilschut J., Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7 Gene Therapy 2002 9 2 85 94 (Pubitemid 34189523)
170. Daemen T., Riezebos-Brilman A., Bungener L., Regts J., Dontje B., Wilschut J., Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7 Vaccine 2003 21 11-12 1082 1088 (Pubitemid 36139938)
171. Riezebos-Brilman A., Regts J., Freyschmidt E. J., Dontje B., Wilschut J., Daemen T., Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice Gene Therapy 2005 12 18 1410 1414 (Pubitemid 43090391)
172. Riezebos-Brilman A., Walczak M., Regts J., Rots M. G., Kamps G., Dontje B., Haisma H. Y., Wilschut J., Daemen T., A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer Gene Therapy 2007 14 24 1695 1704 (Pubitemid 350238446)
173. Riezebos-Brilman A., Regts J., Chen M., Wilschut J., Daemen T., Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12 Vaccine 2009 27 5 701 707
174. de Mare A., Lambeck A. J., Regts J., van Dam G. M., Nijman H. W., Snippe H., Wilschut J., Daemen T., Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition Gene Therapy 2008 15 6 393 403 (Pubitemid 351330997)
175. Walczak M., de Mare A., Riezebos-Brilman A., Regts J., Hoogeboom B-N., Visser J. T., Fiedler M., Jansen-Drr P., Van Der Zee A. G.J., Nijman H. W., Wilschut J., Daemen T., Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine Molecular Pharmaceutics 2011 8 1 65 77